Home ] Up ] Call me back Contents Immunology Infectious agents Cellular Biology Molecular biology Instruments Chimical Product PCR ELISA Sites Komabiotech products ProductHome ] Up ] ID-PNH Test Home | Control blood with platelets / Whole blood for quality control haematology | ID-FMH Screening Test | ID-PNH Test | ID-Sickle Cell Test (HbS)


       Pricelist 2010 


redcoon België GENTAUR BVBA

VAT BE0473327336

Av. de l Armee 68 B4

1040 Brussels BELGIUM

  Tel + 32 16 58 90 45 

Fax + 32 16 50 90 45


SIRET 48423788800017

Rue Lagrange, 9

75005 Paris, France

 Tel 01 43 25 01 50

Fax 01 43 25 01 60 


Marienbongard 20

52074 Aachen, Germany

Tel  0241 56 00 99 68                   

Fax 0241 56 00 47 88 

GENTAUR Pol Sp. Z.o.o.

Ulica Ogarna 15/19B m2

80-826 GDANSK

Tel 00 48 58 760 77 08

Fax: 00 32 16 50 90 45


23015 Milano, Italy

 Tel 02 36 00 65 93

Fax 02 36 00 65 94

Česká republika Praha



Finland Helsset

Ελλάς Αθήνα

Ireland Dublin


Magyarország Budapest


Norge Oslo


Sverige Stockholm

Schweiz Züri


Northern America 

Canada Montreal

US New York


Other Countries redcoon België
0032 (0)16 41 44 07


301, Gayang Technotown, #1487 Gayang 3 dong, Gangseo-gu
Seoul 157-793, KOREA

Sacace Biotechnologies S.r.l.
Via Scalabrini, 44
22100 Como Italy

Spherotech, Inc.
27845 Irma Lee Circle, Unit 101
Lake Forest, IL 60045

Exalpha Biologicals, Inc.
2 Shaker Road, Unit B101
Shirley, MA 01464

Export                                   DF Kasumigaseki Place,3-6-7 Kasumigaseki Chiyoda-ku, Tokyo 100-0013 JAPAN 

EY Laboratories, Inc. Headquarters
107 N. Amphlett Blvd
San Mateo, CA. 94401 USA

EXBIO Praha, a.s.
Nad Safinou II 366
252 42  Vestec
Czech Republic



 ID-PNH Test
ID-Diluent 2 / additional reagent required ID-PNH Test
ID-Diluent 2 / additional reagent required

Modified LISS for red cell suspensions
(Id-n°: 05761)


Pkg. size
Profiles or single test
2 x 100 mL
1 x 500 mL


(Id-n°: 50620)

(Id-n°: 45270)

Rapid test for the diagnosis and therapy monitoring of paroxysmal nocturnal hemogloginuria (PNH).

Reagent 1:
ID-PNH-Gel card with rabbit antiserum against mouse immunoglobulines.

Reagent 2:
Monoclonal antibodies directed against DAF and MIRL respectively, and negative control, ready-to-use, 1.4 mL.

Additionally required: Diluent 2.

A negative control is included in reagent 2.

Gel agglutination assay for PNH via detection of DAF and MIRL by specific monoclonal antibodies. Cells with these antigens bind the mouse antibodies.

After centrifugation through the gel, cells carrying antibodies, confirming the presence of MIRL or DAF, will show a positive reaction. This denotes that the patient does not have PNH.

Negative results or double population confirm the presence of PNH.

Test characteristics:

• very rapid: result in <30 min
• very simple procedure
• very reliable performance*
• economical: unused microtubes in the card can be used at a later time

* Gupta R, et al. A prospective comparison of four techniques for diagnosis of paroxysmal nocturnal hemoglobinuria. Int J Lab Hematol. 2007;29:119-26

Diag. appl.
A test for the exclusion or confirmation of PNH should be considered in patients with otherwise unexplained thrombembolic complications, or in patients with hemolysis or hemorrhage, anemia, and other symptoms.

Patients with PNH have a defective gene called PIG-A, involved in the biosynthesis of glycosyl-phosphatidylinositol (GPI). Without GPI, important regulatory proteins (e.g. CD55 or “DAF”, and CD59 or “MIRL”) cannot bind to the cell surface and protect blood cells from attacks of complement. This may result in a break down of erythrocytes and release of hemoglobin which causes the urine to turn dark during an episode (or “paroxysm”) of hemolysis, though this is not found in all cases.

PNH is an acquired condition induced by exposure to chemicals or certain antibiotics. In many patients their PNH cells may disappear from the blood after some time. Repeating a test for PNH may help to identify patients who are likely to have a spontaneous cure.

Treatment of PNH includes immune-suppressive drugs, supplementation with iron and folic acid. Blood transfusions or anticoagulation may be needed. Soliris™ (Eculizumab, Alexion Pharmaceuticals, Inc., a humanized antibody against complement C5) is a new drug used to treat PNH*. Eculizumab treatment reduces the risk of clinical thromboembolism in patients with PNH**.

*Rother RP, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25:1256-64.

**Hillmen P, et al.. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.Blood. 2007 1;110:4123-8.


Pkg. size
Profiles or single test
1 x 12
24 Profiles
3 x 1 x 1.4 mL
20 Tests